Phase II Study of Paclitaxel and Carboplatin plus Bevacizumab in StageIIIA-N2, IIIB, IV patients with Nonsquamous Non-Small-Cell Lung Cancer

Phase 2

• Conditions: iuml; ve StageIIIA-N2, IIIB, IV patients with nonsquamous non-small-cell lung cancer; chemotherapy-na&amp

• Registration Number: JPRN-UMIN000006809
• Lead Sponsor: Akita University Graduate School of Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-12-01
• Study Completion: 2018-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 31

Inclusion Criteria

Not provided

Exclusion Criteria

1) Radiation therapy(expect chest) 2)Patients with untreated Brain metastases 3)Patients with current or previous history of hemoptysis (2.5mL or more) 4)Patients with uncontrolled hypertension 5)Patients with uncontrolled infection 6)Patients with active lung disease such as interstitial pneumonia, pneumoconiosis, active radiation pneumonitis, pulmonary fibrosis or drug-induced pneumonitis 7)Patients with uncontrollable complications 8)Patients with massive pleural or pericardial effusion,or ascites 9)Patients with active concomitant malignancy 10)Patients with previous histories of drug allergy 11)Patients with uncontrollable gastrointestinal ulceration 12)Patients with current or previous (within one year) history of gastrointestinal perforation 13)Patients with therapeutic anticoagulopathy (including Aspirin over 325mg/day) 14)Pregnancy or lactation 15)Inappropriate patients for this study judged by the physicians

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Response Rate

Secondary Outcome Measures

Name	Time	Method
Endothelial progenitor cells as biomarker Safety Maximum reduction rate of primary tumor size Resectability rate as induction therapy Progression Free survival Over all survival